荧光原位杂交检测乳腺癌HER2扩增状态及其-中国普通外科杂志.pdf

652 2018 45 9  Cancer Res Prev Treat,2018,Vol.45,No.9 · · 肿瘤防治研究 年第 卷第 期 doi:10.3971/j.issn.1000-8578.2018.18.0179 · · 临床研究 HER2 ++ 荧光原位杂交检测乳腺癌 （ ）扩增 状态及其与临床病理的相关性 张明帅，王胄，蒋威华，李涌涛，甫拉提·吾瓦力汉，欧江华 HER2 (++) Amplification in Breast Cancer Detected by Fluorescence in Situ Hybridization and Its Correlation with Clinicopathological Features ZHANG Mingshuai, WANG Zhou, JIANG Weihua, LI Yongtao, FULATI·Wuwalihan, OU Jianghua Department of Breast Surgery, Affiliated Tumor Hospital, Xinjiang Medical University, Urumqi 830011, China Corresponding Author: OU Jianghua, E-mail: oujianghua@ Abstract: Objective To detect the amplification of HER2 gene by fluorescence in situ hybridization(FISH), and explore the correlation between HER2 gene amplification and clinicopathological characteristics. Methods We collected 325 cases of breast cancer with HER2(++) in the Affiliated Tumor Hospital of Xinjiang Medical University from January 2013 to December 2015. All paraffin-embedded specimens were detected by IHC and FISH respectively for the expression of HER2 protein and amplification. And we analyzed the relationship between HER2 gene amplification and clinicopathological characteristics of patients. Results HER2(++) of all groups was detected immunohistochemically. And the amplification rate of HER2 gene was 12.9%(42/325). Univariate analysis on 12 clinicopathological indexes showed that the amplification status of HER2 gene was significantly correlated with hormonal status, tumor diameter and P53, rather than ki67 expression, histological grade, tumor number or other factors. Conclusion Th